Overcoming Treatment Resistance in HER2-Positive Breast Cancer

@article{Puglisi2012OvercomingTR,
  title={Overcoming Treatment Resistance in HER2-Positive Breast Cancer},
  author={PhD Dr Fabio Puglisi and Alessandro Marco Minisini and Martin Hrab{\'e} de Angelis and Grazia Arpino},
  journal={Drugs},
  year={2012},
  volume={72},
  pages={1175-1193}
}
Human epidermal growth factor receptor (HER)-2 overexpression or amplification occurs in about 20% of all breast cancers and results in a worse prognosis. Nevertheless, anti-HER2 treatments have recently been developed, resulting in dramatic improvements in the clinical outcome of patients with HER2-positive breast cancer. Trastuzumab has shown efficacy in early and advanced breast cancer treatment and lapatinib is currently approved for the treatment of advanced disease. Other anti-HER2 agents… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 127 REFERENCES

Similar Papers

Loading similar papers…